282 related articles for article (PubMed ID: 9506788)
1. Activation of the clotting system: heparin-coated versus non coated systems for extracorporeal circulation.
Urlesberger B; Zobel G; Rödl S; Dacar D; Friehs I; Leschnik B; Muntean W
Int J Artif Organs; 1997 Dec; 20(12):708-12. PubMed ID: 9506788
[TBL] [Abstract][Full Text] [Related]
2. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants.
Urlesberger B; Zobel G; Zenz W; Kuttnig-Haim M; Maurer U; Reiterer F; Riccabona M; Dacar D; Gallisti S; Leschnik B; Muntean W
J Pediatr; 1996 Aug; 129(2):264-8. PubMed ID: 8765625
[TBL] [Abstract][Full Text] [Related]
3. [D-dimer, thrombin-antithrombin III-complex (TAT) and prothrombin fragment 1+2 (PTF). Parameters for monitoring therapy with low molecular-weight heparin in coagulation disorders].
Hofmann M; Rest A; Hafner G; Tanner B; Brockerhoff P; Weilemann LS
Anaesthesist; 1997 Aug; 46(8):689-96. PubMed ID: 9382207
[TBL] [Abstract][Full Text] [Related]
4. Global and extended coagulation monitoring during extracorporeal lung assist with heparin-coated systems in ARDS patients.
Gerlach M; Föhre B; Keh D; Riess H; Falke KJ; Gerlach H
Int J Artif Organs; 1997 Jan; 20(1):29-36. PubMed ID: 9062829
[TBL] [Abstract][Full Text] [Related]
5. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
6. Does heparin pretreatment affect the haemostatic system during and after cardiopulmonary bypass?
Brinks HJ; Weerwind PW; Bogdan S; Verbruggen H; Brouwer MH
Perfusion; 2001 Jan; 16(1):3-12. PubMed ID: 11192305
[TBL] [Abstract][Full Text] [Related]
7. Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO).
Zavadil DP; Stammers AH; Willett LD; Deptula JJ; Christensen KA; Sydzyik RT
J Extra Corpor Technol; 1998 Jun; 30(2):83-90. PubMed ID: 10182118
[TBL] [Abstract][Full Text] [Related]
8. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
[TBL] [Abstract][Full Text] [Related]
9. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
Herren T; Straub PW; Haeberli A
Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
[TBL] [Abstract][Full Text] [Related]
10. Low dose systemic heparinization combined with heparin-coated extracorporeal circulation. Effects related to platelets.
Mirow N; Brinkmann T; Minami K; Tenderich G; Schulte-Eistrup S; Kleesiek K; Körfer R
J Cardiovasc Surg (Torino); 2001 Oct; 42(5):579-85. PubMed ID: 11562580
[TBL] [Abstract][Full Text] [Related]
11. Influence of heparin treatment on biochemical markers of an activation of the coagulation system.
Amelsberg A; Zurborn KH; Gärtner U; Kiehne KH; Preusse AK; Bruhn HD
Thromb Res; 1992 May; 66(2-3):121-31. PubMed ID: 1412188
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
13. Twenty-four-hour heparin-free veno-right ventricular ECMO: an experimental study.
Koul B; Vesterqvist O; Egberg N; Steen S
Ann Thorac Surg; 1992 Jun; 53(6):1046-51. PubMed ID: 1596127
[TBL] [Abstract][Full Text] [Related]
14. Experimental evaluation of a heparin coated ECMO system simplified with a centrifugal pump.
Matsuwaka R; Matsuda H; Kaneko M; Miyamoto Y; Sakagoshi N; Kuratani T; Chang JC; Kawashima Y; Hagiwara K; Fukazawa H
ASAIO Trans; 1990; 36(3):M473-5. PubMed ID: 2123638
[TBL] [Abstract][Full Text] [Related]
15. Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model.
Sakai M; Ohteki H; Narita Y; Naitoh K; Natsuaki M; Itoh T
Cardiovasc Surg; 1999 Mar; 7(2):187-94. PubMed ID: 10353669
[TBL] [Abstract][Full Text] [Related]
16. The effect of prophylactic heparin treatment on enhanced thrombin generation in pregnancy.
Bremme K; Lind H; Blombäck M
Obstet Gynecol; 1993 Jan; 81(1):78-83. PubMed ID: 8416465
[TBL] [Abstract][Full Text] [Related]
17. Effects on blood compatibility in vitro by combining a direct P2Y12 receptor inhibitor and heparin coating of stents.
Christensen K; Larsson R; Emanuelsson H; Elgue G; Larsson A
Platelets; 2006 Aug; 17(5):318-27. PubMed ID: 16928604
[TBL] [Abstract][Full Text] [Related]
18. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
Maul TM; Wolff EL; Kuch BA; Rosendorff A; Morell VO; Wearden PD
Pediatr Crit Care Med; 2012 Nov; 13(6):e363-71. PubMed ID: 22940857
[TBL] [Abstract][Full Text] [Related]
19. The antithrombin III-saving effect of reduced systemic heparinization and heparin-coated circuits.
Ranucci M; Cazzaniga A; Soro G; Isgrò G; Frigiola A; Menicanti L
J Cardiothorac Vasc Anesth; 2002 Jun; 16(3):316-20. PubMed ID: 12073203
[TBL] [Abstract][Full Text] [Related]
20. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
Elgue G; Blombäck M; Olsson P; Riesenfeld J
Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
